Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023
Intercept's fireside chat will take place from
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
For more information about Intercept, please contact:
Investor inquiries: email@example.com
Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.